NeoImmuneTech is currently conducting multiple clinical trials of its lead asset NT-I7 in multiple indications, both as a monotherapy and in combination with other therapeutics, including checkpoint inhibitors and more.

NeoImmuneTech is also continuing to conduct proof-of-concept animal studies in additional indications to further broaden the proof of the applicability of NT-I7.
NT-I7 (efineptakin alfa) Development Program
Program Study Indication Combination Preclinical Phase 1 Phase 2 Phase 3 Collaborator Link
NT-I7 Combination Therapy
NIT-110 Solid Tumors 5 KEYTRUDA ® Phase 1b/2a 새창으로 열기
NIT-119 NSCLC 1L TECENTRIQ ® Phase 2 새창으로 열기
NIT-120 Recurrent GBM KEYTRUDA ® Phase 2    새창으로 열기
Chemo/Radio NIT-107 Newly diagnosed GBM 3 CCRT 6 Phase 1/2    새창으로 열기
CAR-T NIT-112 Large B-cell lymphoma (LBCL) KYMRIAH ®,
Phase 1b 새창으로 열기
Vaccine NIT-124 Head & Neck squamous cell carcinoma (HNSCC/SCCHN) KEYTRUDA ®,
Phase 2 새창으로 열기
NT-I7 Monotherapy
NT-I7 mono NIT-113 Progressive Multifocal Leukoencephalopathy (PML) 2 Pilot 새창으로 열기
NIT-114 Idiopathic CD4 lymphopenia (ICL) 1 Phase 1/2
NIT-115 Squamous cell carcinoma of head and neck (SCCHN/HNSCC) Phase 1 새창으로 열기
NIT-A01 Acute Radiation Syndrome 4 Preclinical

  • 1. Orphan Drug Designation (EU May 2017 US Apr. 2019)
  • 2. Orphan Drug Designation (US Jun. 2020)
  • 3. Orphan Drug Designation (US Jul. 2022)
  • 4. Orphan Drug Designation (US Nov. 2023)
  • 5. Pancreatic cancer, Orphan Drug Designation (US Jan. 2024)
  • 6. Concurrent Chemoradiotherapy
  •  Investigator-initiated trial